Cargando…

Direct Medical Cost of Type 2 Diabetes in Singapore

Due to the chronic nature of diabetes along with their complications, they have been recognised as a major health issue, which results in significant economic burden. This study aims to estimate the direct medical cost associated with type 2 diabetes mellitus (T2DM) in Singapore in 2010 and to exami...

Descripción completa

Detalles Bibliográficos
Autores principales: Shuyu Ng, Charmaine, Toh, Matthias Paul Han Sim, Ko, Yu, Yu-Chia Lee, Joyce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376523/
https://www.ncbi.nlm.nih.gov/pubmed/25816299
http://dx.doi.org/10.1371/journal.pone.0122795
_version_ 1782363750824673280
author Shuyu Ng, Charmaine
Toh, Matthias Paul Han Sim
Ko, Yu
Yu-Chia Lee, Joyce
author_facet Shuyu Ng, Charmaine
Toh, Matthias Paul Han Sim
Ko, Yu
Yu-Chia Lee, Joyce
author_sort Shuyu Ng, Charmaine
collection PubMed
description Due to the chronic nature of diabetes along with their complications, they have been recognised as a major health issue, which results in significant economic burden. This study aims to estimate the direct medical cost associated with type 2 diabetes mellitus (T2DM) in Singapore in 2010 and to examine both the relationship between demographic and clinical state variables with the total estimated expenditure. The National Healthcare Group (NHG) Chronic Disease Management System (CDMS) database was used to identify patients with T2DM in the year 2010. DM-attributable costs estimated included hospitalisations, accident and emergency (A&E) room visits, outpatient physician visits, medications, laboratory tests and allied health services. All charges and unit costs were provided by the NHG. A total of 500 patients with DM were identified for the analyses. The mean annual direct medical cost was found to be $2,034, of which 61% was accounted for by inpatient services, 35% by outpatient services, and 4% by A&E services. Independent determinants of total costs were DM treatments such as the use of insulin only (p<0.001) and the combination of both oral medications and insulin (p=0.047) as well as having complications such as cerebrovascular disease (p<0.001), cardiovascular disease (p=0.002), peripheral vascular disease (p=0.001), and nephropathy (p=0.041). In this study, the cost of DM treatments and DM-related complications were found to be strong determinants of costs. This finding suggests an imperative need to address the economic burden associated with diabetes with urgency and to reorganise resources required to improve healthcare costs.
format Online
Article
Text
id pubmed-4376523
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43765232015-04-04 Direct Medical Cost of Type 2 Diabetes in Singapore Shuyu Ng, Charmaine Toh, Matthias Paul Han Sim Ko, Yu Yu-Chia Lee, Joyce PLoS One Research Article Due to the chronic nature of diabetes along with their complications, they have been recognised as a major health issue, which results in significant economic burden. This study aims to estimate the direct medical cost associated with type 2 diabetes mellitus (T2DM) in Singapore in 2010 and to examine both the relationship between demographic and clinical state variables with the total estimated expenditure. The National Healthcare Group (NHG) Chronic Disease Management System (CDMS) database was used to identify patients with T2DM in the year 2010. DM-attributable costs estimated included hospitalisations, accident and emergency (A&E) room visits, outpatient physician visits, medications, laboratory tests and allied health services. All charges and unit costs were provided by the NHG. A total of 500 patients with DM were identified for the analyses. The mean annual direct medical cost was found to be $2,034, of which 61% was accounted for by inpatient services, 35% by outpatient services, and 4% by A&E services. Independent determinants of total costs were DM treatments such as the use of insulin only (p<0.001) and the combination of both oral medications and insulin (p=0.047) as well as having complications such as cerebrovascular disease (p<0.001), cardiovascular disease (p=0.002), peripheral vascular disease (p=0.001), and nephropathy (p=0.041). In this study, the cost of DM treatments and DM-related complications were found to be strong determinants of costs. This finding suggests an imperative need to address the economic burden associated with diabetes with urgency and to reorganise resources required to improve healthcare costs. Public Library of Science 2015-03-27 /pmc/articles/PMC4376523/ /pubmed/25816299 http://dx.doi.org/10.1371/journal.pone.0122795 Text en © 2015 Shuyu Ng et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Shuyu Ng, Charmaine
Toh, Matthias Paul Han Sim
Ko, Yu
Yu-Chia Lee, Joyce
Direct Medical Cost of Type 2 Diabetes in Singapore
title Direct Medical Cost of Type 2 Diabetes in Singapore
title_full Direct Medical Cost of Type 2 Diabetes in Singapore
title_fullStr Direct Medical Cost of Type 2 Diabetes in Singapore
title_full_unstemmed Direct Medical Cost of Type 2 Diabetes in Singapore
title_short Direct Medical Cost of Type 2 Diabetes in Singapore
title_sort direct medical cost of type 2 diabetes in singapore
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376523/
https://www.ncbi.nlm.nih.gov/pubmed/25816299
http://dx.doi.org/10.1371/journal.pone.0122795
work_keys_str_mv AT shuyungcharmaine directmedicalcostoftype2diabetesinsingapore
AT tohmatthiaspaulhansim directmedicalcostoftype2diabetesinsingapore
AT koyu directmedicalcostoftype2diabetesinsingapore
AT yuchialeejoyce directmedicalcostoftype2diabetesinsingapore